Beyond analysts' top-and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
2026 has marked a significant turning point in biotech capital markets, not just a small comeback. Venture funding for biotech startups reached $9.1 billion in the first half of the year, the highest
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $420 to $400.
Dublin, July 21, 2026 (GLOBE NEWSWIRE) -- The "Biomarker Collaboration and Licensing Deals 2016-2026" has been added to ResearchAndMarkets.com's offering.This report provides a comprehensive and struc
View interactive chart, options flow, and AI analysis for ALNY on Zorveq Finance.
Open ALNY Chart & Analysis →